Key facts
- It has raised $9.8M across 2 recorded rounds; the latest was Early Stage VC ($6.2M) in Mar 2023.
- Notable investors include Matter (Consulting Services (B2B)).
- Adze Biotechnology has filed 5 Form Ds with the SEC since 2022, most recently Nov 2025 ($6.2M sold to 21 investors).
- Status: Privately Held (backing).
Investors
1- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Adze Biotechnology
Funding rounds
2 roundsAbout Adze Biotechnology
Developer of oncologic immunotherapies designed to help in the treatment of cancers with significant unmet needs. The company's immunotherapies harness immune response mechanisms and target immune stimulatory and inhibitory receptors, dendritic cells, and macrophages to further amplify the immune response, enabling healthcare professionals to increase patient survival and improve patient quality of life through reduced side effects.
- Sector
- Healthcare
- HQ
- Coral Gables, FL, United States
- Founded
- 2018
- Employees
- 2
- Website
- adzebiotech.com/
- Ownership
- Privately Held (backing)
Adze Biotechnology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Adze Biotechnology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Adze Biotechnology in its N-PORT filings yet. We sweep new filings monthly.